-+ 0.00%
-+ 0.00%
-+ 0.00%

Longeveron says Phase 2b trial shows laromestrocel improves physical condition in age-related frailty patients

PUBT·09/30/2026 20:09:15
Longeveron says Phase 2b trial shows laromestrocel improves physical condition in age-related frailty patients
  • Longeveron highlighted Phase 2b results showing its laromestrocel cell therapy improved physical condition in age-related frailty patients versus placebo.
  • Those findings were already published in February 2026, supporting efforts to secure funding and other revenue opportunities for a longevity program.
  • A new exploratory analysis from its Phase 2a Alzheimer’s study was posted as a preprint, indicating reduced brain inflammation with treatment.
  • The Alzheimer’s analysis has not been peer reviewed, leaving clinical and commercial implications uncertain.
  • Longeveron received a $1 million XPRIZE Healthspan Milestone 2 award to support a future competition clinical trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301605PRIMZONEFULLFEED9837091) on September 30, 2026, and is solely responsible for the information contained therein.